These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 33290767)

  • 1. Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches.
    Raj V; Park JG; Cho KH; Choi P; Kim T; Ham J; Lee J
    Int J Biol Macromol; 2021 Jan; 168():474-485. PubMed ID: 33290767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M
    Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity.
    Hamdy R; Fayed B; Mostafa A; Shama NMA; Mahmoud SH; Mehta CH; Nayak Y; M Soliman SS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease.
    Marinho EM; Batista de Andrade Neto J; Silva J; Rocha da Silva C; Cavalcanti BC; Marinho ES; Nobre Júnior HV
    Microb Pathog; 2020 Nov; 148():104365. PubMed ID: 32619669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of SARS-CoV-2 Main Protease Inhibitors from a Library of Minor Cannabinoids by Biochemical Inhibition Assay and Surface Plasmon Resonance Characterized Binding Affinity.
    Liu C; Puopolo T; Li H; Cai A; Seeram NP; Ma H
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
    Ghosh A; Chakraborty M; Chandra A; Alam MP
    J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring epigenetic drugs as potential inhibitors of SARS-CoV-2 main protease: a docking and MD simulation study.
    Uzuner U; Akkus E; Kocak A; Çelik Uzuner S
    J Biomol Struct Dyn; 2024 Aug; 42(13):6892-6903. PubMed ID: 37458994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 M
    Citarella A; Scala A; Piperno A; Micale N
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of bio-active Amaryllidaceae alkaloidal small molecules as putative SARS-CoV-2 main protease and host TMPRSS2 inhibitors: interpretation by
    Bhowmick S; Mistri TK; Khan MR; Patil PC; Busquets R; Ashif Ikbal AM; Choudhury A; Roy DK; Palit P; Saha A
    J Biomol Struct Dyn; 2024 Sep; 42(14):7107-7127. PubMed ID: 37482789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
    Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
    Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Philippsen GS; Seixas FAV
    J Biomol Struct Dyn; 2024 Aug; 42(12):6440-6447. PubMed ID: 37424215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.
    Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC
    J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olive-Derived Triterpenes Suppress SARS COV-2 Main Protease: A Promising Scaffold for Future Therapeutics.
    Alhadrami HA; Sayed AM; Sharif AM; Azhar EI; Rateb ME
    Molecules; 2021 May; 26(9):. PubMed ID: 34062737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
    Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
    Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization.
    Abo Elmaaty A; Hamed MIA; Ismail MI; B Elkaeed E; S Abulkhair H; Khattab M; Al-Karmalawy AA
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34205704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico screening of potential inhibitors from Cordyceps species against SARS-CoV-2 main protease.
    Deshmukh N; Talkal R; Lakshmi B
    J Biomol Struct Dyn; 2024 Jun; 42(9):4395-4411. PubMed ID: 37325819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
    Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
    Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.